Endometriosis Drugs: Global Strategic Business Report

Global Endometriosis Drugs Market to Reach $3.3 Billion by 2030

The global market for Endometriosis Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$3.3 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2022-2030. Hormone therapy, one of the segments analyzed in the report, is projected to record 3% CAGR and reach US$2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analgesics segment is readjusted to a revised 2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $777.8 Million, While China is Forecast to Grow at 2.4% CAGR

The Endometriosis Drugs market in the U.S. is estimated at US$777.8 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.3% and 2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Select Competitors (Total 38 Featured) -

• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bayer AG
• Debiopharm Group
• Evotec AG
• Kissei Pharmaceutical Co. Ltd.
• Neurocrine Biosciences Inc.
• ObsEva SA
• Pfizer Inc.
• Repros Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
• ValiRx plc

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year